In early March, we met with the SEC Crypto Task Force. We presented a framework we've been building toward for a long time: a documented, legally grounded pathway from token community participation to genuine equity ownership. Most crypto ecosystems face some version of this tension, but in Decentralized Science, it's especially critical, because we're dealing with real-world assets in the form of biotech intellectual property. Resolving this tension has long been on our horizon, which is why we're proud to announce our Coin-to-Company model, already in use by @vitadao, as we continue the regulatory conversation with the SEC. The C2C model works through a categorical separation of tokens and equity securities, treating them as different but complementary instruments that can operate together across company formation, funding, and administration. Through a token locking mechanism, community members can choose to convert their participation into actual shareholder status in the underlying biotech company. All tokenholders remain part of a project-focused DAO throughout. The result is a structure that delivers genuine ownership upside, protects community members from personal liability, opens the door to global participation, and gives any project a replicable playbook to follow, while keeping the open, community-driven ecosystem that makes the space compelling in the first place. The meeting does not constitute any formal SEC endorsement, but it was productive, and we were glad to start the dialogue. Read the announcement & let us know what you think.

Two questions every early-stage research project eventually has to answer: > Where is the science right now? > What should happen next? MIRA, our AI research assistant, was built to answer both, grounded in a project's own live data. The full breakdown is published today.

"The Compliant Path from Community to Cap Table" Ben, Chief Legal Officer at @Molecule_sci, on how token holders can follow a legally grounded route to gain genuine equity ownership in the projects they support.

GLP-1R has more published binding data than almost any receptor in metabolic medicine. The @peptai_ GLP-1R programme exists to connect autonomous peptide design to wet lab validation, end to end, for the first time. A receptor with decades of known agonists and confirmed binding affinities gives the pipeline something it cannot get elsewhere. Every computational score can be measured against biology where the answer is already known. Four peptides are running now. > C2-01 and C2-03A are novel candidates designed autonomously through all eight computational gates. > GLP-1(7-36)amide is the calibration anchor with a confirmed Kd of 140 nM already measured by Adaptyv Bio. > Ala7-GLP-1 is the negative control. GenScript handles synthesis and ships the peptides direct to Adaptyv Bio Lausanne for BLI binding kinetics. The full cycle from synthesis to first binding data runs six to seven weeks. Total wet lab cost sits at ~$4,200–4,600. First data expected in Q3 2026. Every result publishes openly on @Molecule_sci Labs regardless of outcome.

Science is getting faster, more modular, and increasingly run by autonomous agents. @DeSciBerlin returns for its 5th edition on June 18-19, in the heart of Kreuzberg during Berlin Blockchain Week. Two days built around scientific singularity and agentic science, for scientists, AI engineers, biotech founders, and anyone working toward a more open, accelerated research economy. On the main stage: > AI robotics in the wet lab > Peptide discovery by AI agents > Agentic swarms for science > Longevity and rejuvenation > Lessons from the biotech hedge fund manager > and more Plus hands-on workshops: > Decentralized Science onboarding for academic researchers > Vibecoding for science: getting useful research out of AI > Branding and marketing for your project The next decade of science is being shaped in rooms like this one. We're looking forward to hosting you.

What happens when AI becomes the researcher? At @DeSciBerlin, @marco_derossi from @MetaMask explained why blockchain will be essential for keeping research structured, connected, and verifiable in an AI-driven future.

Excited to share more details. So many folks are curious. I’m telling you, for innovators, crypto-funding and DeSci are really cool ways to build companies.

Michael @Mykalt45 just sold CrossBridge Bio to Eli Lilly for up to $300M. Now he's leading ARTANBio ($VITARNA), a @vitadao-backed gene therapy program going after premature termination codons in aging. At DeSci Berlin, he'll walk through what changes when biotech funding captures upside earlier.

The @vitarnabio team just closed a $200K raise to take their engineered suppressor platform into animal studies, building on the fundraising through Molecule Protocol. You'll be able to catch @Mykalt45 speaking at @DeSciBerlin, fresh out of his $300M exit to @EliLillyandCo!

Every decision the agents make is publicly verifiable. Every gate decision, tool call, pass, and failure is published openly on @molecule_sci. Agents mint their own IP NFTs and log the full audit trail on-chain. Computational analysis stays publicly verifiable. Wet lab results can be held private until the team decides on disclosure. Agent announcements on new library designs and gate outcomes will be published on a weekly cadence.

Institutional capital arriving, AI-driven research compounding, and projects reaching clinical stages at a pace that would embarrass many traditionally funded biotechs. Great write-up by @beakerdao

Autism Spectrum Disorder (ASD) is a lifelong neurodevelopmental condition that shapes how individuals communicate, connect, and experience the world. Every person on the spectrum has unique strengths, challenges, and support needs. Through innovative At Home research efforts, families can play an active role in helping scientists better understand autism in real-world settings, from developmental patterns to individualized support pathways. By making participation more accessible, researchers can gather meaningful insights that may help improve understanding and future care. In collaboration with the Molecule Science Foundation, the CRASD Token initiative supports a community-driven approach to advancing autism research. Participation helps strengthen long-term scientific efforts focused on inclusion, early understanding, and building better support systems for individuals and families impacted by autism. Every voice, every family, and every contribution helps shape a future with greater awareness, stronger communities, and more informed research. Accessible for families. Meaningful for science. Support the mission and learn more: Link: moleculesciencefoundation.or… #AutismResearch #ASDAwareness #PediatricResearch #OryanHealth #HealthcareInnovation